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ABSTRACT
Introduction Over the last two decades, the use of 
opioids for the treatment of chronic pain in England 
has steadily increased despite lack of evidence of both 
long- term effectiveness in pain relief and significant, 
well- documented physical and mental adverse events. 
Guidelines recommend tapering when harms outweigh 
benefits, but the addictive nature of opioids hinders simple 
dose- reduction strategies. Improving the Well- being of 
people with Opioid Treated CHronic pain (I- WOTCH) trial 
tests a multicomponent self- management intervention 
aimed to help patients with chronic non- malignant pain 
taper opioid doses. This paper outlines the methods 
to be used for the economic analysis of the I- WOTCH 
intervention compared with the best usual care.
Methods and analysis Economic evaluation alongside 
the I- WOTCH study, prospectively designed to identify, 
measure and value key healthcare resource use and 
outcomes arising from the treatment strategies being 
compared. A within- trial cost- consequences analysis and 
a model- based long- term cost- effectiveness analysis 
will be conducted from the National Health Service and 
Personal Social Service perspective in England. The former 
will quantify key parameters to populate a Markov model 
designed to estimate the long- term cost and quality- 
adjusted life years of the I- WOTCH intervention against 
best usual care. Regression equations will be used to 
estimate parameters such as transition probabilities, 
utilities, and costs associated with the model’s states 
and events. Probabilistic sensitivity analysis will be used 
to assess the impact of parameter uncertainty onto the 
predicted costs and health outcomes, and the resulting 
value for money assessment of the I- WOTCH intervention.
Ethics and dissemination Full ethics approval was 
granted by Yorkshire & The Humber—South Yorkshire 
Research Ethics Committee on 13 September 2016 (16/
YH/0325). Current protocol: V.1.7, date 31 July 2019. 
Findings will be disseminated in peer- reviewed journals, 
scientific conferences, newsletters and websites.
Trial registration number International Standard 
Randomised Controlled Trial Number (49 470 934); Pre- 
result.
BACKGROUND
Nearly half of the UK adult population (43%) 
is living with chronic pain (ie, pain lasting >3 
months), the prevalence of which increases 
with age.1 Opioids are commonly prescribed 
for chronic pain and a recent study reports 
an increase in the number of opioid prescrip-
tions (approximately 34%) in England 
between 1998 and 2016.2 Analysis of prescrip-
tion data shows that after this long increasing 
trend, there is a slight decrease in the 
annual number of opioid prescriptions for 
pain since 2016.3 Despite the demonstrated 
short- term effectiveness of opioids, evidence 
of their long- term impact in terms of pain 
relief and improvement in functional status 
is scant.4 5 This situation is compounded by 
concerns over the fact that long- term use 
of opioids can lead to adverse events (at an 
Strengths and limitations of this study
 ► First economic evaluation of a complex interven-
tion Improving the Well- being of people with Opioid 
Treated CHronic pain (I- WOTCH) to support opioid 
tapering.
 ► The economic analyses use patient- level informa-
tion to inform a de- novo decision model.
 ► I- WOTCH’s decision model will enable estimation of 
the costs, health consequences, and uncertainty as-
sociated with opioid use and tapering over a lifetime 
horizon.
 ► Valuable evidence for potential implementation of 
the self- management support intervention aimed at 
opioid tapering.
 ► Uncertainties may remain as to the long- term ef-
fectiveness and cost- effectiveness of the I- WOTCH 
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estimated absolute rate of 78% in trials using a placebo 
as a comparator) affecting the respiratory, cardiovascular, 
gastrointestinal and central nervous systems.6 These 
include common adverse events such as dry mouth, 
nausea and constipation, as well as more serious adverse 
events including sleep- disordered breathing, respiratory 
depression and opioid- related deaths (at an absolute rate 
of 7.5%).6–8 Equally concerning is the fact that opioid use 
is associated with mental health and anxiety disorders, 
major depression and dysthymia.9 Their long- term use 
may cause problematic patterns of substance use, leading 
to substance use disorders (ie, abuse and dependence).10 
Risk factors for opioid- related adverse events include 
older age, higher doses of this class of drugs and their 
long- term use.11 12
Clinical guidelines for prescribing opioids in chronic 
pain recommend tapering when the possible harms from 
their use outweigh any expected benefits13 and yet, to our 
knowledge, no validated protocol or intervention exists 
to help patients reduce their opioid doses and manage 
their chronic pain.14 A number of studies have evalu-
ated interventions (eg, acupuncture, ketamine- assisted 
dose reduction and behavioural strategies such as moti-
vational interviewing, psychiatric consultation, cogni-
tive behavioural therapy and mindfulness) that support 
opioid tapering.15–18 The conclusions drawn by these 
studies are limited by the quality of their design or insuffi-
cient follow- up period.14 Relevant for our study, there are 
no existing economic evaluations of opioid- tapering strat-
egies in the management of chronic non- malignant pain.
Improving the Well- being of people with Opioid 
Treated CHronic pain (I- WOTCH) is a National Institute 
for Health Research- funded randomised controlled trial 
(RCT) evaluating the effectiveness and cost- effectiveness 
of a patient- centred, multicomponent self- management 
intervention targeting withdrawal of strong opioids 
among those living with chronic non- malignant pain.19 
The I- WOTCH trial is designed to help people reduce 
their opioid consumption, manage pain interference and 
enhance their quality of life.
This paper describes the protocol for the economic 
analysis that has been designed as an integral part of the 
I- WOTCH trial.
METHODS
Study details (population, setting, location, intervention and 
comparator)
A detailed study protocol for the I- WOTCH trial has been 
reported in a separate manuscript.19 Briefly, I- WOTCH 
is a multisite, patient- centred, open RCT enrolling adult 
patients with non- malignant chronic pain in England. The 
trial’s target sample size is 542 participants, individually 
randomised (1:1) to receive the I- WOTCH intervention 
or best usual care. The I- WOTCH intervention is an 8–10 
weeks’ course—consisting of a mixture of group sessions 
led by two trained I- WOTCH facilitators, two one- to- one 
individual sessions and two telephone consultations with 
the I- WOTCH- trained nurse facilitator—adjunct to best 
usual care. Best usual care consists of general practitioner 
(GP) care with relaxation package and a booklet called 
‘My Opioid Manager’.
Planned start and end dates
The I- WOTCH study started in September 2016 and is 
expected to end in March 2021. The economic analysis is 
expected to begin in October 2020.
Type of economic evaluation (cost-consequences and cost-
effectiveness analyses)
Two types of economic analysis will be conducted: a 
within- trial cost- consequences analysis (CCA) and a long- 
term model- based cost- effectiveness analysis (CEA), the 
details of these are provided in the Analysis section.
Study perspective
The perspective for both the CCA and CEA will be that of 
the National Health Service and Personal Social Service 
for England.
Time horizon
The CCA and CEA will adopt a 12- month and a patients’ 
life time horizons, respectively.
Discount rate
Estimates of mean cost and health benefits observed 
during the 12- month trial follow- up period will not be 
discounted (for the purpose of the CCA), while those 
predicted to accrue beyond the study follow- up (for the 
purpose of the CEA) will be discounted using a 3.5% 
annual discount rate as per National Institute for Health 
and Care Excellence (NICE) guidelines.20
Identification, measurement and valuation of health outcomes
Table 1 describes the variables of interest to the economic 
analyses of I- WOTCH, the frequency of data collection 
and data sources.
The CCA will consider the following three health 
outcome measures over the 12- month trial follow- up 
period:
1. Activities of Daily Living (ADL)—measured using the 
Patient Reported Outcomes Measurement Information 
System pain intensity short form- 8A questionnaire 
(PROMIS- PI- SF- 8A).21
2. Severity of opioid withdrawal symptoms—measured using 
the Short Opiate Withdrawal Scale (ShOWS).22
3. The 5- level EQ- 5D version (EQ- 5D- 5L) instrument—a 
preference- based generic measure of health- related 
quality of life typically used in healthcare economic 
evaluation.23 24
The PROMIS- PI- SF- 8A comprises eight questions rated 
on a scale of 1–5 that aim to measure the degree of inter-
ference of pain on day- to- day activities, work around the 
home, ability to participate in social activities, household 
chores, fun activities, enjoyment of social activities, enjoy-
ment of life and family life. The total raw score is the sum 
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Table 1 Data collection strategy for I- WOTCH’s economic analyses
Data collected Source Time of collection
Baseline data   
  Age PtQ Baseline
  Gender PtQ Baseline
  Ethnic group PtQ Baseline
  Current work status PtQ Baseline
  Age at leaving full time education PtQ Baseline
  Pain duration PtQ Baseline
  Opioid intake duration PtQ Baseline
  Pain conditions PtQ
GPRs
Baseline
At 12 months only
  Pain severity stratification group PtQ Baseline
Measures of health benefit   
  Activities of daily living (PROMIS- PI- SF- 8A) PtQ Baseline, 4, 8 and 12 months
  Severity of opioid withdrawal symptoms (ShOWS) PtQ
PtD
Baseline, 4, 8 and 12 months
Weekly over first 4 months
  Generic health- related quality of life (EQ- 5D- 5L) PtQ
PtD
Baseline, 4, 8 and 12 months
Weekly over first 4 months
Resource use (volume, admissions, consultations, attendances and/or contacts)   
  Medications PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  Hospital PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  Hospital outpatient PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  GP surgery PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  GP home PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  GP telephone GPRs At 12 months only
  Practice nurse PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  Practice nurse telephone GPRs At 12 months only
  District nurse (ie, at home) PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
  NHS 111 GPRs At 12 months only
  Occupational therapist PtQ Baseline, 4, 8 and 12 months
  Counsellor PtQ Baseline, 4, 8 and 12 months
  Psychologist PtQ Baseline, 4, 8 and 12 months
  Social worker PtQ Baseline, 4, 8 and 12 months
  Physiotherapist PtQ Baseline, 4, 8 and 12 months
  Referrals GPRs At 12 months only
  Investigations GPRs At 12 months only
  Ambulance incidents GPRs At 12 months only
  Accident and emergency GPRs At 12 months only
  Other PtQ
GPRs
Baseline, 4, 8 and 12 months
At 12 months only
EQ- 5D- 5L, 5- level EQ- 5D version; GP, general practitioner; GPRs, GP records; I- WOTCH, Well- being of people with Opioid Treated 
CHronic pain; NHS, National Health Service; PROMIS- PI- SF- 8A, Patient- Reported Outcomes Measurement Information System pain 
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maximum score of 40 and a minimum score of 8. Higher 
scores reflect large interference or change in partici-
pant’s ability to perform daily activities. This instrument 
supports calculation of a common metric and will be 
converted to a T score.21
ShOWS identifies the severity of opiate withdrawal 
symptoms on 10 different categories namely: feeling 
sick, stomach cramps, muscle spasms, feeling of cold-
ness, heart pounding, muscular tension, aches and pains, 
yawning, runny eyes and insomnia. The response to each 
question is attributed to an individual score of 0–3, with 
0 indicating no symptoms, 1 mild, 2 moderate and 3 
severe.22 Higher overall scores (estimated as the sum of 
all individual scores with a maximum score of 30 and a 
minimum score of 0) indicate higher severity of opioid- 
withdrawal symptoms.
The EQ- 5D- 5L Questionnaire23 describes health in 
five domains (mobility, self- care, usual activities, pain or 
discomfort, and anxiety or depression). Each domain has 
five levels of severity (1—no problems/2—slight prob-
lems/3—moderate problems/4—severe problems/5—
unable to do). A response consists of a sequence of five 
digits, for example, 12315, 12112, which represent the 
level of severity on each domain reported by the respon-
dent. Combinations of the levels of the five domains 
describe 3125 possible health states. Several valuation 
studies have been carried out in the literature to esti-
mate value sets for a given country/region. These studies 
used methods consistent with economic theory to elicit 
the respondent’s preferences towards the health states 
defined by the EQ- 5D. A value set to calculate utility 
values for the EQ- 5D- 5L has been published recently25 
but is still subject to methodological controversy. Until 
the controversies are resolved, we will convert EQ- 5D- 5L 
responses onto the EQ- 5D- 3L scale using the mapping 
function developed by van Hout et al26 following current 
NICE’s recommendation.24
The CEA will integrate predicted survival and EQ- 5D 
index scores (for each model state and clinical event) to 
derive an estimate of quality- adjusted life years (QALYs)—
the health benefit of choice in our CEA—under the 
I- WOTCH and best usual care strategies.
Identification, measurement and valuation of resource use
As described in table 1, patient- level resource use data are 
collected in the trial and will be complemented by infor-
mation routinely collected in GP records. Costing will 
be carried out in UK pound sterling at 2019 prices. Unit 
cost for tests, investigations, inpatient hospital admissions 
and day care procedures will be estimated using National 
Reference Costs and Healthcare Resource Group codes.27 
Referrals and consultations will be costed using Personal 
and Social Services Research Unit (PSSRU) statistics.28 If 
necessary, we will use unit costs from previous versions 
of the PSSRU report29 30 and inflate them to the year 
2019 using inflation and price indices from the Office of 
National Statistics (ONS).31 Costs associated with usual 
care will include the cost of the relaxation CD (ie, printing 
and production costs) and ‘My Opioid Manager’.
Microcosting of I-WOTCH intervention
A microcosting of the resources required to provide the 
I- WOTCH intervention will be conducted. A detailed 
description of the categories of resource use to be consid-
ered, their associated unit costs and the data collection 
forms used in the I- WOTCH microcosting exercise is 
provided in the online supplemental tables A1‒4. Salary, 
facility and travel costs will be assumed to be independent 
of the number of participants. Salaries for the facilitators 
and trainers will be estimated based on average daily salary 
by grade. The facility costs will be calculated based on the 
number of venues hired, number of days hired and daily 
venue hire rate. Travel costs will be considered as fixed 
cost per mile. Unit costs for nurses’ time for face- to- face 
and telephone consultations will be extracted from the 
PSSRU 2019.28 A per participant, locality and course cost 
of I- WOTCH intervention will be reported.
Cost of medication
Unit costs of the medications (table 1) will be obtained 
from the British National Formulary (BNF).32 For each 
strength and preparation of a given pain killer drug, we 
will extract the cost per pack (or bottle) from the BNF and 
we will calculate the relevant morphine equivalent dose 
(MED) using the same algorithm used in the I- WOTCH 
clinical analysis. This is being updated from that used to 
estimate MED for stratification at the time of randomisa-
tion. For each opioid- based medication reported to have 
been used by individuals in the I- WOTCH study, we will 
estimate their unit cost per MED and use it to estimate a 
weighted average cost per MED over all opioid medica-
tions used in the trial.
Modelling
A Markov state- transition model was developed to facil-
itate the estimation of the long- term mean costs and 
QALYs associated with the I- WOTCH intervention and 
usual care. The initial conceptual structure of the model 
was informed by a systematic analysis of the components 
of the I- WOTCH intervention. This task was supported 
and enhanced by critically appraising published deci-
sion models that evaluated the use of opioids in chronic 
non- malignant pain. The face validity of the model struc-
ture was further refined by holding a series of meetings 
with the project team involving clinical experts from the 
I- WOTCH study. This process is described in detail in a 
separate related manuscript currently in preparation.
Figure 1 depicts a schematic representation of our final 
model structure, which is organised around five key states 
(ie, represented as ovals in figure 1). At any time period, 
patients can be in one of the following mutually exclu-
sive states: (a) long- term opioid therapy (LTOT)—repre-
senting individuals candidate for the intervention, who 
have been using strong opioids for more than 3 months; 
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to tapering as part of the I- WOTCH intervention; (c) 
patient- driven tapering (PT)—individuals self- committed 
to tapering without the intervention; (d) successful 
opioid- less management of pain (SOLMP)—individuals 
completed withdrawal from opioid use; and (e) dead (D).
Each state is associated with an average cost and utility 
score, derived using the methods described in the Statis-
tical analysis section. Spearheads of arrows in figure 1 
represent the directions of allowed transitions per cycle. 
LTOT is the starting state for all patients in the I- WOTCH 
trial. Individuals in LTOT can engage with IT only once 
but are able to initiate PT at their will. While they remain 
in the LTOT state, individuals can experience opioid- 
related transient/emergent adverse events or persistent/
serious adverse events. Occasionally, adverse events may 
trigger a transition from LTOT to PT. Individuals in IT 
or PT may withdraw from opioid tapering at any point 
in time and go back to LTOT. Individuals in IT or PT 
can transit to SOLMP state only when they are no longer 
taking any opioids. Finally, individuals are at risk of death 
at any point in time (ie, transitions into the absorbing 
D state are allowed from the LTOT, IT, PT and SOLMP 
states). A paper providing a detailed description of the 
conceptualisation of the model, health states definition, 
clinical events and associated transitions is in prepara-
tion. To maximise the use of the data collected during 
the trial and to model the events and transitions observed 
during the treatment and follow- up period, the state tran-
sition model uses a weekly cycle length during the first 4 
months and monthly cycles beyond that.
ANALYSIS
Statistical analysis for the CCA and CEA will be conducted 
using I- WOTCH’s individual patient data (IPD) collected 
on resource use and outcomes, analysed on an intention- 
to- treat (ITT) basis. Statistical analysis and decision 
models will be implemented in R.33
Within-trial cost-consequences analysis
The CCA will focus on estimating and reporting mean 
health outcomes, resource use and costs by treatment 
arm at each follow- up interval. No incremental analysis 
will be conducted. Total costs will be the sum of the costs 
of the healthcare resource items (described in table 1) 
that patients used during the study period, plus the cost 
Figure 1 Simplified model structure showing patient flow during the I- WOTCH trial. At any time, individuals will be allocated to 
any five health states (shown as ovals). Individuals start in the long- term opioid therapy (LTOT) health state. Depending on the 
trial arm, they will move to either I- WOTCH tapering (IT) or patient- driven tapering (PT). The transition from LTOT to IT occurs 
only at the start of the trial and patients cannot go back to IT once they withdraw from it. Patients who have tapered their opioid 
doses completely will be in the successful opioid- less management of pain (SOLMP) health state. Patients may withdraw from 
IT or PT to move to LTOT health state. Similarly, patients in SOLMP may move to LTOT if they restart their opioid doses. The 
arrows‘ spearheads indicate the direction of allowed transition from one state to the other. Dead (D) state is an absorbing state 
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of either the I- WOTCH intervention or the usual care. 
Mean health outcomes will include those described in the 
Identification, measurements and valuation section and 
be reported at each follow- up period by treatment arm.
Handling missing data
We will assess the extent of missing data in the patient- level 
costs and health outcomes collected during I- WOTCH’s 
12- month follow- up and apply appropriate methods to 
handle the issue following the recommendations by Faria 
et al.34
Statistical analysis
Descriptive statistics (ie, mean, SD, lower and upper 
quartiles, minimum and maximum values) for all contin-
uous variables reported in table 1 plus total costs will be 
estimated by trial arm. Histograms and/or box- plots will 
be used to represent these variables graphically. Binary 
and categorical variables will be represented in terms of 
percentages. The impact of patient’s baseline characteris-
tics (ie, age, gender, pain severity, opioid use, duration of 
opioid intake and opioid medication- related pain condi-
tion) as predictors of outcomes will be explored in a series 
of regression models fitted to ADL, ShOWS, EQ- 5D- 3L 
utility scores and cost data to inform the estimation of the 
Markov model’s input parameters.
We will map EQ- 5D- 5L utility scores into EQ- 5D- 3L 
utility scores.24 26 To account for idiosyncrasies of the 
EQ- 5D- 3L (ie, multimodality, truncated support and 
left- skewness), we will use a series of regression models 
(including mixture of beta models, adjusted limited 
dependent variable mixture models, two- part models). 
Each model goodness of fit and assessment of their 
predictive ability will be carried out using the methods 
recommended by Hernandez et al.35 36
Many methods have been used to analyse cost data.37 
We will use generalised linear models (with Gaussian or 
gamma distributed errors and identity or log links) and 
where necessary, two- part extensions of these models to 
account for any mass at zero, the right skewed nature 
of the dependent variable and possible heteroskedas-
ticity. Should administrative censoring (due to patients’ 
differential follow- up) be present, the analysis will use 
inverse probability weighting methods alongside our cost- 
regression models.38
All regression models will explore the impact of the 
patient’s baseline characteristics included in table 1, and 
use these results to explore the role of patients’ hetero-
geneity onto the cost- effectiveness results (more in the 
Subgroup analysis section).
Sensitivity analysis
For the purposes of the CCA, we will carry out a per- 
protocol analysis and compare the results from the ITT. 
We will calculate the minimum versus actual number of 
group sessions needed to provide the I- WOTCH inter-
vention to all participants in the intervention group. We 
will also consider a minimum and maximum number 
of participants per course observed in the I- WOTCH 
trial. We will use a one- way or threshold analyses on the 
assumptions made on estimating the costs.
Long-term model-based cost-effectiveness analysis
Populating model parameters
Table 2 provides a list of key model parameters and 
the source for initial values, that is, mean, SD or CI. To 
estimate all model initial values, we will use IPD from 
the I- WOTCH trial and GP records as well as any rele-
vant publicly available evidence. Transitions from all 
model states to death will be extracted from age and sex 
adjusted all- cause mortality statistics from the ONS.39 
Transition probabilities between all the other model 
states will be derived using risk equations from regres-
sion models (eg, time- to- event and/or logit- regression 
models depending on the nature of the transition). 
Costs and utilities parameters for each of the model 
states and events will be estimated using the regression 
models described in the Statistical analysis section. Vari-
ance–covariance matrices for each of the regressions will 
be extracted to inform the parameter uncertainty esti-
mates in the model and used in the probabilistic sensi-
tivity analysis (PSA) as explained in the Probabilistic 
sensitivity analyses section.
Incremental analysis
We will estimate the differential costs and QALYs 
predicted by the model and—where relevant—calculate 
the incremental cost- effectiveness ratio (ICER), defined 
as the ratio between the mean difference in costs and the 
mean difference in QALYs. As decision makers need to 
assess whether an intervention is ‘value for money’, we will 
compare the ICER against two ‘thresholds’: one ranging 
between £20 000 and £30 000 per QALY gained to mimic 
the criterion used by NICE for its policy decisions, and 
another recently proposed by Lomas et al who estimated 
this threshold to be between £5000 and £15 000.40
Subgroup analysis
In order to reflect variation between individuals in terms 
of their health benefit, resource use and costs, we will run 
the Markov state transition model for a series of different 
patient profiles. This will enable us to reflect the impact 
that patient characteristics may have on the value for 
money assessment of I- WOTCH. The rationale for this 
approach stems from the recognition that the baseline 
risk (and possibly the treatment effect) may vary between 
individuals based on their opioid use, pain severity and 
pain conditions. The trial’s predefined subgroups based 
on baseline variables are as follows: (1) pain severity score 
(5–8, 9–11 and 12–15); (2) opioid usage in MED (0–20 
mg, 30–59 mg, 60–89 mg, 90–119 mg, 120–149 mg and 
>=150 mg); (3) pain conditions (fibromyalgia, muscu-
loskeletal, arthritis, back pain, neurological, cancer and 
other) and (4) duration of opioid intake (less than 1 year, 
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Probabilistic sensitivity analyses
Sampling uncertainty in the model will be captured by 
characterising each model parameter with an appropriate 
probability distribution. We will derive the parameters to 
inform these distributions from the variance–covariance 
matrix obtained from each regression model. Cholesky 
decomposition of each variance–covariance matrix will 
be used to make the simulation more efficient. Sampling 
uncertainty will be propagated through the model using 
Monte- Carlo simulation in the form of PSA to understand 
Table 2 Model parameters to inform long- term decision analytic model
Transition probability Sources Specific details of the fields in source
Remaining in IT NTP
NCRF
Time of withdrawal from IT
Time of withdrawal from IT
LTOT to IT The trial Proportion of people engaged in IT
IT to LTOT NTP
NCRF
Time of withdrawal from IT
Time of withdrawal from IT
IT to SOLMP NTP
NCRF
Time of completely stopping the use of opioids
Time of completely stopping the use of opioids
IT to dead state PL All- cause mortality data from ONS
Remaining in LTOT The trial Number of people who do not engage in IT and remain in LTOT








LTOT to dead state PL All- cause mortality data from ONS
Remaining in PT The trial
PtQ
GPRs
Number of people who remain in PT over time
Medication data
Prescription data








PT to dead state PL All- cause mortality data from ONS




SOLMP to dead state All- cause mortality rates from ONS
Utility scores Source Specific details of the source
LTOT PL
PtQ
Utility of opioid therapy45
Regression analysis of patient self- reported EQ- 5D
PT PtQ Regression analysis of patient self- reported EQ- 5D
IT PtQ Regression analysis of patient self- reported EQ- 5D
SOLMP PtQ Regression analysis of patient self- reported EQ- 5D




Cost of opioid therapy per cycle46
Costs associated with self- reported resource use




Cost associated with usual care
Costs associated with self- reported resource use
Costs associated with resource use collected
IT The trial Cost associated with intervention
SOLMP PL Assumption—1× contact with GP28
‘The trial’ means the I- WOTCH trial.
GP, general practitioner; GPRs, GP records; IT, I- WOTCH tapering; I- WOTCH, Improving the Well- being of people with Opioid Treated CHronic 
pain; LTOT, long- term opioid therapy; NCRF, nurse clinical record form; NTP, nurse tapering plan; ONS, Office of National Statistics; PL, 
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the effect on the predicted mean QALYs and mean costs 
associated with each treatment arm. These parameters 
will then be combined and compared against a range of 
feasible cost- effectiveness thresholds to obtain an esti-
mate of the probability that I- WOTCH is cost- effective. 
This information will be represented graphically in the 
form of a cost- effectiveness acceptability curve.41 Also, we 
will perform scenario analyses for the various distribu-
tional assumptions made, for example, on the parametric 
survival distribution and compare the results for different 
assumptions.
DISCUSSION
The scale of the opioid crisis in the UK is not as severe 
as in the USA. However, recently, it has been reported 
that opiates are a frequent cause of death due to drug 
poisoning in the UK.3 42 To begin reviewing the bene-
fits and risks of opioid medicine, and make recommen-
dations for regulatory action, an expert working group 
has been formed by the Medicines and Healthcare Prod-
ucts Regulatory Agency.43 This protocol describes the 
first economic evaluation of an adjunct intervention (ie, 
I- WOTCH) to support opioid tapering in patients with 
chronic non- malignant pain. Its findings will provide 
timely and significant results to inform policy recommen-
dations on how best to tackle the opioids epidemic in 
the UK and manage the complex landscape of opioids- 
related health (and financial) risks.
A study that tested the effectiveness of an earlier 
version of I- WOTCH (ie, the COPERS trial/COping 
with persistent Pain, Effectiveness Research into Self- 
management) showed sustained benefits on depression 
and anxiety in people with musculoskeletal chronic 
pain.44 The COPERS intervention was designed based 
on cognitive behavioural therapy principles. While in the 
COPERS trial more than 20% of participants used strong 
opioids, this was not aimed at opioid dose reduction. 
In contrast, the I- WOTCH intervention was designed to 
support opioid reduction and improve activities of daily 
living.
Strengths
This paper describes the first economic evaluation anal-
ysis of a complex intervention to support opioid tapering, 
which uses data collected alongside the first UK- based 
RCT. A within- trial CCA will allow estimating relevant 
model parameters. The long- term impact on costs and 
health benefits from implementing the I- WOTCH 
Programme in England will be assessed in a lifetime 
decision analytic model populated using trial and previ-
ously published data. This analysis is based on a robust 
conceptual model that reflects clinical practice and long- 
term adverse events associated with both opioid use and 
opioid withdrawal. This model will enable estimation of 
I- WOTCH’s cost- effectiveness over a lifetime horizon and 
real- life subgroup analyses.
Limitations
Our decision problem and associated model structure are 
complex. I- WOTCH’s effectiveness in the short and long 
term is associated to the occurrence/absence of several 
interlinked events that determine individual’s transition 
from one health state to the other. I- WOTCH’s 12- month 
trial follow- up period is unlikely to allow to capture all 
events of interest in the long term. This may limit our 
ability to estimate all relevant transition probabilities on 
trial- based IPD. A number of model parameters may need 
to be estimated from published sources and experts’ 
opinion. Data availability may limit the successful evalua-
tion of the CEA model.
ETHICS AND DISSEMINATION
The study was approved by the Yorkshire & The 
Humber—South Yorkshire Research Ethics Committee 
(16/YH/0325). Appropriate local approvals were sought 
for each area in which recruitment was undertaken. The 
current protocol version is 1.7 date 31 July 2019. To inform 
all health technology assessment stakeholders, our results 
will be published in peer reviewed journals and presented 
at scientific conferences. Similarly, I- WOTCH’s newsletter 
and lay summaries of our results on the study’s website 
will be our main vehicles to disseminate our findings to 
study participants and facilitators.
PATIENT AND PUBLIC INVOLVEMENT
The involvement of patient and public in the interven-
tion design, development and delivery is outlined in 
the I- WOTCH clinical protocol paper.19 In brief, two 
lay advisers with chronic pain withdrawal of opioids and 
experience of clinical trial research have been recruited 
to the study. Additionally, prior to receiving funding 
for the study, meetings were held with volunteers with 
chronic malignant pain to receive input to the design of 
the intervention structure, duration of intervention and 
content to be covered. These meetings contributed also 
to the design of the study including randomisation, best 
usual care intervention, recruitment processes, as well as 
outcome measures.
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